Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02996825
Title Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

triple-receptor negative breast cancer

endometrial cancer

ovarian cancer

fallopian tube cancer

peritoneum cancer

Therapies

Gemcitabine + Mirvetuximab Soravtansine

Age Groups: senior | adult | child
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Medical Center Duarte California 91010 United States Details
City of Hope Upland Upland California 91786 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field